siRNA therapy decreases triglycerides in people with rare disorder

.STUDY HIGHLIGHT.19 September 2024.

Plozasiran decreased triglyceride amounts by 80% and reduced the danger of pancreatitis in individuals with chronic chylomicronemia, along with or without a hereditary diagnosis.